COVID-19 Evidence Reviews
as of 9/30/22
menu
 
 

Long COVID
 
= living review
= draft/preprint   |  
= meets mimimum quality standards   |  

A review with this mark was peer-reviewed, described systematic search and study selection, and included critical appraisal of primary studies.
latest update
date
report
select
9/20/22
Keikha M, Karbalaei M | Microb Pathog
Aim: To investigate the effect of polymorphisms such as rs4646994 and rs2285666 on susceptibility to coronavirus disease-2019 (COVID-19).
LONG COVID
9/19/22
Kulper-Schiek W, Piechotta V, Pilic A, et al. | Front Immunol
Aim: To summarize evidence on the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine (vaccine effectiveness, VE) and duration of protection against Omicron.
LONG COVID
9/19/22
Pellegrino R, Chiappini E, Licari A, et al. | Eur J Pediatr
Aim: To summarize the current evidence regarding Long COVID in children, with a focus on prevalence and clinical presentation.
LONG COVID
9/6/22
Notarte KI, Catahay JA, Velasco JV, et al. | EClinicalMedicine
Aim: To review the evidence on the impact of COVID-19 vaccines on the risk of developing long-COVID or on existing long-COVID in COVID-19 survivors.
LONG COVID
9/6/22
Tariq M, Acharekar MV, Guerrero Saldivia SE, et al. | Cureus
Aim: To focus on the two main long-standing symptoms, fatigue and headaches, resulting in poor work performance and difficulty in performing daily activities of life.
LONG COVID
8/30/22
Joli J, Buck P, Zipfel S, et al. | Front Psychiatry
Aim: To describe all symptoms related to post-COVID-19 fatigue, its possible etiology and risk factors as well as treatment approaches employed so far.
LONG COVID
8/29/22
Muchtaridi M, Amirah SR, Harmonis JA, et al. | Antioxidants
Aim: To review the evidence on the prospect of utilizing natural antioxidants as long-term treatment for COVID-19 via the Nrf2 signaling pathway. 
LONG COVID
8/26/22
Greer N, Bart B, Billington CJ, et al. | BMJ Open
Aim: To examine major organ damage postdischarge among adults hospitalised for COVID-19 versus non-COVID-19 controls.
UPDATED
VA ESP
LONG COVID
8/26/22
Choudhury A, Tariq R, Jena A, et al. | Therap Adv Gastroenterol
Aim: To assess the GI manifestation of ‘long COVID’ and the frequency of these manifestations.
LONG COVID
8/23/22
Habibzadeh A, Lankarani KB, Farjam M, et al. | Curr Fungal Infect Rep
Aim: To investigate the prevalence and outcomes of fungal drug-resistant in COVID-19 patients.
LONG COVID
8/22/22
Mavraganis G, Dimopoulou MA, Delialis D, et al. | Eur J Clin Invest
Aim: To synthesize current evidence on the frequency and the prognostic value of vascular dysfunction during acute and post-recovery COVID-19.
LONG COVID
8/18/22
Ali SS, Mumtaz A, Qamar MA, et al. | Ann Med Surg
Aim: To highlight Parkinsonism as a post-COVID-19 sequela and helps us understand a possible link between the two.
UPDATED
LONG COVID
8/15/22
Bryant MC, Spencer LT, Yalcindag A | Pediatr Rheumatol Online J
Aim: To present a case of new-onset AAV following COVID-19 infection in an adolescent patient, and we review the literature of AAV following COVID-19 infection.
LONG COVID
8/15/22
Nag AK, Saltagi AK, Saltagi MZ, et al. | Ann Otol Rhinol Laryngol
Aim: To establish whether a consensus exists regarding optimal management of olfactory dysfunction and to provide insight into the treatment of anosmia in the current climate of increased prevalence secondary to COVID-19. 
LONG COVID
8/9/22
Gualano MR, Rossi MF, Borrelli I, et al. | Work
Aim: To evaluate the impact of lasting COVID-19 symptoms or disability on the working population upon their return to employment.
LONG COVID
7/29/22
Bailly M, Pélissier L, Coudeyre E, et al. | Int J Environ Res Public Health
Aim: To systematically review the effects of physical activity programs in the recovery of post-COVID-19 patients. 
UPDATED
LONG COVID
7/27/22
Elhiny R, Al-Jumaili AA, Yawuz MJ | Int J Pharm Pract
Aim: To describe the COVID-19 complications after recovery.
LONG COVID
7/15/22
 | NSW Health COVID-19 Critical Intelligence Unit
Aim: To review the evidence on the effectiveness of exercise in helping individuals with COVID-19 to recover, and if post-exertional symptom exacerbation is a risk in long COVID.
LONG COVID
7/6/22
Pinzon RT, Wijaya VO, Jody AA, et al. | J Infect Public Health
Aim: To conduct a systematic review and meta-analysis on the persistent neurological manifestations in COVID-19 survivors.
LONG COVID
5/23/22
Castanares-Zapatero D, Chalon P, Kohn L, et al. | Ann Med
Aim: To conduct a comprehensive review to address the putative pathophysiology underlying the persisting symptoms of long COVID.
LONG COVID
5/4/22
 | NSW Health COVID-19 Critical Intelligence Unit
LONG COVID
4/19/22
Chen C, Haupert SR, Zimmermann L, et al. | J Infect Dis
Aim: To examine the worldwide prevalence of post COVID-19 condition.
LONG COVID
3/31/22
Abdel-Gawad M, Zaghloul MS, Abd-Elsalam S, et al. | Antiinflamm Antiallergy Agents Med Chem
Aim: To assess the prevalence of post-COVID-19 manifestations.
LONG COVID
2/21/22
Yelin D, Moschopoulos CD, Margalit I, et al. | Clin Microbiol Infect
Aim: To provide evidence-based recommendations for assessment and management of individuals with persistent symptoms after acute COVID-19 infection, and provide a definition for this entity, termed “long COVID”.
LONG COVID
2/14/22
Nguyen NN, Hoang VT, Dao TL, et al. | Eur J Clin Microbiol Infect Dis
Aim: To describe the burden of the long-term persistence of clinical symptoms in COVID-19 patients.
LONG COVID
1/13/22
Macpherson K, Cooper K, Harbour J, et al. | BMJ Open
Aim: To explore the experiences of people living with long COVID and how they perceive the healthcare services available to them.
LONG COVID
12/4/21
Decary S, Dugas M, Stefan T, et al. | SPOR
Aim: To review the evidence on care models for persons living with long COVID.
UPDATED
LONG COVID
10/12/21
Sandler CX, Wyller VBB, Moss-Morris R, et al. | Open Forum Infect Dis
Aim: To review the evidence on post-COVID fatigue.
LONG COVID
9/30/21
Michelen M, Manoharan L, Elkheir N, et al. | BMJ Glob Health
Aim: To regularly synthesise evidence on long COVID characteristics, to help inform clinical management, rehabilitation strategies and interventional studies to improve long-term outcomes.
LONG COVID
6/21/21
Amdal CD, Pe M, Falk RS, et al. | Qual Life Res
Aim: To identify all relevant health-related quality of life (HRQoL) issues associated with COVID-19.
LONG COVID
5/13/21
Martimbianco ALC, Pacheco RL, Bagattini AM, et al. | Int J Clin Pract
Aim: To identify, systematically evaluate and summarise the best available evidence on the frequency of long COVID (post-acute COVID-19 syndrome), its clinical manifestations and the criteria used for diagnosis.
UPDATED
LONG COVID
4/26/21
Iwu CJ, Iwu CD, Wiysonge CS | Pan Afr Med J
Aim: To synthesize evidence on the long-term effects of the SARS-CoV-2 infection among survivors.
LONG COVID
4/20/21
Pizarro-Pennarolli C, Sánchez-Rojas C, Torres-Castro R, et al.  | PeerJ
Aim: To understand the impact of COVID-19 on ADL performance of adult patients and to describe the common scales used to assess performance of ADL on patients post-COVID-19.
LONG COVID
3/31/21
Vollbracht C, Kraft K | Nutrients
Aim: To provide a feasibility analysis of whether the use of intravenous (IV) vitamin C in post-viral fatigue, particularly after COVID-19, should be further investigated. 
LONG COVID